IGC Pharma(IGC) - 2024 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-32830 IGC PHARMA, INC. (Exact name of registrant as specified in its charter) Maryland (State or other jurisdiction of incorporation or organization) Washington, D.C. 20549 FORM 10-Q 10224 Falls Road, Poto ...